SELLAS Life Sciences Group, Inc. (SLS)

Every figure this model derived for SLS, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2023-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2016-12-31
cash 138,343,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 142,505,000 AssetsCurrent 2026-06-30
current liabilities 7,569,000 LiabilitiesCurrent 2026-06-30
equity 137,656,000 StockholdersEquity 2026-06-30
revenue 0 RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31
sbc 0 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up SLS on one particular measure came for.

RatioValue
current ratio18.83
current ratio reported18.83
deferred revenue growth-100.0
growth cv3.26
revenue growth-100.0
revenue growth per share-100.0
rpo growth0.0

What to be careful about

What this model itself distrusts about SLS's figures. Written by the derivation as it ran, not added afterwards.